gimsilumab   Click here for help

GtoPdb Ligand ID: 9624

Synonyms: MORAb-022
Immunopharmacology Ligand
Compound class: Antibody
Comment: Gimsilumab (MORAb-022) is an investigational, fully human IgG1 monoclonal antibody being evaluated for its potential in the treatment of multiple inflammatory diseases and cancer. It targets granulocyte-macrophage colony stimulating factor (GM-CSF, CSF2), a growth factor involved in autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and asthma. In the cancer setting, MORAb-022-mediated blocking of CSF2 produces a pro-immunity microenvironment that leads to tumour tissue death in preclinical studies. Peptide sequences (from the WHO INN submission for gimsilumab) match sequences 8 and 12 from Morphotek Inc. patent WO2007092939 [1], and these sequences belong to monoclonal antibody clone G9 specified in the patent.
No information available.
Summary of Clinical Use Click here for help
Phase 1 study (NCT01357759) in healthy volunteers and patients with rheumatoid arthritis has been completed.

SARS-CoV-2 and COVID-19: In response to the urgent medical need caused by SARS-CoV-2, gimsilumab is being investigated for anti-inflammatory potential in COVID-19 patients. The hypothesis being to reduce the raging cytokine storm that can arise secondary to SARS-CoV-2 infection.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01357759 Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects Phase 1 Interventional Morphotek
NCT04351243 A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19. Phase 2 Interventional Kinevant Sciences GmbH A repurposing effort to try to meet the unmet clinical need of patients with severe COVID-19.